Keyphrases
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Phase II Trial
100%
Transplantation
100%
Human Islets
100%
Severe Hypoglycemia
100%
Severe Hypoglycemic Event
100%
Hypoglycemia Unawareness
87%
Immunosuppression
50%
Human Pancreatic Islets
50%
Bleeding
25%
Phase II Study
12%
Islet Transplantation
12%
Disability
12%
Hemoglobin A1c (HbA1c)
12%
Glomerular Filtration Rate
12%
Glycemic Control
12%
Transfusion
12%
Patients at Risk
12%
Less Invasive
12%
Medical Treatment
12%
Current Treatment
12%
Current Therapies
12%
Donor-specific Antibodies
12%
Safety Events
12%
Good Manufacturing Practice
12%
Practice Conditions
12%
Release Criteria
12%
Stimulated C-peptide
12%
Lot Release
12%
Release Test
12%
Investigational Product
12%
Number of Patients
12%
Reduced Kidney Function
12%
Medicine and Dentistry
Insulin Dependent Diabetes Mellitus
100%
Antidiabetic Agent
100%
Severe Hypoglycemia
100%
Hypoglycemia
87%
Awareness
87%
Immunosuppressive Treatment
50%
Pancreatic Islet
50%
Patient with Type 1 Diabetes
25%
Islet Transplantation
12%
Combination Therapy
12%
Infection
12%
Arm
12%
Glycemic Control
12%
Kidney Function
12%
Bleeding
12%
Glomerular Filtration Rate
12%
Infusion
12%
Hemoglobin A1c
12%
C-Peptide
12%
Ciclonicate
12%